Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, engages in development and marketing of disruptive technology for novel sublingual delivery mechanisms in the United States. The company offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. It also develops formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, the company develops formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. Aspire Biopharma Holdings, Inc. was founded in 2021 and is headquartered in Humacao, Puerto Rico.